Related Experiment Videos
Serum concentrations of soluble HLA-class I and CD8 forms in patients with viral hepatic disorders
M Hagihara1, T Shimura, K Takebe
1Department of Transplantation Immunology, Tokai University School of Medicine, Kanagawa, Japan.
Insights
Soluble HLA-class I and CD8 levels are elevated in patients with viral hepatitis, liver cirrhosis, and liver cancer. These markers may indicate immune system activity rather than just liver damage.
Area of Science:
- Immunology
- Hepatology
- Virology
Background:
- Viral-induced hepatic disorders are a significant global health concern.
- Understanding the immunological markers associated with liver disease progression is crucial for diagnosis and treatment.
- Soluble human leukocyte antigen class I (sHLA-class I) and CD8 molecules are implicated in immune responses.
Purpose of the Study:
- To investigate the levels of soluble HLA-class I and CD8 molecules in patients with various viral-induced hepatic disorders.
- To explore the correlation between these soluble molecules and disease severity or progression.
- To determine if sHLA-class I and sCD8 levels reflect hepatic destruction or immunological activity.
Main Methods:
- Sandwich ELISA was employed to quantify sHLA-class I and sCD8 levels in patient serum.
- Patients included those with acute hepatitis (AH), chronic hepatitis (CH), liver cirrhosis (LC), and hepatocellular carcinoma (HCC).
- Data were analyzed to compare levels between patient groups and normal controls, and to assess correlations with disease stage and biochemical parameters (GPT, GOT).
Main Results:
- Patients with hepatic disorders exhibited significantly higher sHLA-class I and sCD8 levels than healthy controls.
- Acute hepatitis (AH) patients showed the highest sHLA-class I levels, followed by CH, LC, and HCC.
- sCD8 levels were highest in AH, followed by HCC, LC, and CH.
- Among hepatitis C virus-positive patients, sHLA-I levels decreased with disease progression (CAH 2A > CAH 2B > LC).
- sCD8 levels showed minimal variation across different hepatic disorders.
- sHLA-class I levels positively correlated with sCD8 values in the overall patient cohort and in AH patients.
- No correlation was observed between sHLA-class I or sCD8 levels and biochemical liver function tests (GPT, GOT).
Conclusions:
- Elevated sHLA-class I and sCD8 levels are characteristic of viral-induced hepatic disorders.
- These soluble molecules may serve as indicators of immunological activity rather than solely reflecting hepatic tissue damage.
- Further research into sHLA-class I and sCD8 as biomarkers for monitoring immune responses in liver diseases is warranted.
Abstract:
Soluble HLA-class I and CD8 molecules were determined by sandwich ELISA in patients with viral-induced hepatic disorders. As a whole, the patients with hepatic disorders (acute hepatitis: AH; chronic hepatitis: CH; liver cirrhosis: LC; hepatocellular carcinoma: HCC) showed higher sHLA-class I and sCD8 levels than normal controls (P < 0.001). AH patients had the highest sHLA-class I levels (mean, 3513 +/- 2112 ng/ml), followed by CH (2896 +/- 1290 ng/ml), LC (2293 +/- 1266 ng/ml), and HCC (2221 +/- 1212 ng/ml) sCD8 levels wer highest in AH, followed by HCC, LC, and CH, in that order. Among histologically defined C virus-positive patients, sHLA-I levels were higher in those with chronic active hepatitis (CAH) 2A (3802 +/- 1124 ng/ml) than in those with chronic persistent hepatitis (CPH; 2200 +/- 711 ng/ml; P < 0.01), the levels then decreased as the disease progressed (CAH2B, 3564 +/- 1783 ng/ml, LC, 2376 +/- 1265 ng/ml). In contrast, sCD8 values showed little difference among the disorders. sHLA-class I levels showed a positive correlation with sCD8 values both in whole patients and in patients with AH (P < 0.01), but no correlation was shown, in any patients, with biochemical parameters such as GPT and GOT. These findings, taken together, suggest that hepatic destruction is not the only cause of sHLA-class I production, but that sHLA-class I levels, together with sCD8 levels, may reflect immunological activity in hepatic disorders.